SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)
$IRMD
Medical/Dental Instruments
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/12/2023 | $50.00 | Buy | Lake Street |
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will attend the Goldman Sachs 47th Annual Global Healthcare Conference, to be held June 8–10, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida. Investors interested in meeting with Iradimed management during the conference may contact their Goldman Sachs representative to schedule a one-on-one meeting. About IRADIMED CORPORATION IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI"
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on May 29, 2026. ORLANDO, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD)
ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7676b33322324840ad2b154cc8e65b88. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-time
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00
SCHEDULE 13G/A - IRADIMED CORP (0001325618) (Subject)
10-Q - IRADIMED CORP (0001325618) (Filer)
8-K - IRADIMED CORP (0001325618) (Filer)
WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,
Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on May 29, 2026. ORLANDO, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD)
ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7676b33322324840ad2b154cc8e65b88. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-time
Reports record revenue of $22.7 million for the fourth quarter of 2025, an increase of $3.3 million, or 17%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0.54 for the fourth quarter of 2025, which are increases of 25% and 23%, respectively, compared to the same period in 2024. Reports record GAAP diluted EPS of $1.75 and non-GAAP diluted EPS of $1.93 for the full year of 2025, which are increases of 17% and 16%, respectively, compared to the full year of 2024. Declares a regular quarterly cash dividend of $0.20 per share of common stock for the fourth quarter of 2025, payable on March 6, 2026. ORLANDO, Fla., Feb. 10, 2026 (G
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)